Human Activin RII (Luc) HEK293 Reporter Cell

用户评价
货号-规格
价格
Qty.
CHEK-ATF164-2Vials (1Vial X 2)
询价
合计0件 产品金额¥ 0

产品详情

    1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
    2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
    3. Comprehensive application data to support assay development and validation
    4. Full tracible record, stringent quality control and validated cell passage stability
    5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
    6. Global commercial license assistance whenever regulatory filing is required
  • 描述(Description)

    The Human Activin RII (Luc) HEK293 Reporter Cell was engineered to express Smad signaling response element driving luciferase expressing systems. When stimulated with multiple ligands, including activin, myostatin and GDF-11, receptor-mediated signaling can drive Smad-mediated luminescence. Neutralization of biological effect of the ligand-receptor interaction by corresponding antibody results in a decrease in luminescence.

  • 应用说明(Application)

    • Screen for neutralizing antibodies blocking the ligand-receptor interaction.

    Activin RII Assay Principles

  • 生长特性(Growth Properties)

    Adherent

  • 筛选标记(Selection Marker)

    Puromycin (2 μg/mL)

  • 培养基(Complete Growth Medium)

    DMEM + 10% FBS

  • 冻存液(Freeze Medium)

    Serum-free cell cryopreservation medium

  • 装量(Quantity)

    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

  • 存储(Storage)

    Frozen in liquid nitrogen.

  • 支原体检测(Mycoplasma Testing)

    Negative

  • 无菌检测(Sterility Testing)

    Negative

  • 使用说明(Instructions for Use)

    See data sheet for detailed culturing and assay protocol.

  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • Application

     Activin RII APPLICATION

    Inhibition of human Activin A protein-induced reporter activity by anti-Activin RII neutralizing antibody.
    This reporter cell was incubated with serial dilutions of antibodies in the presence of human Activin A protein (Cat. No. ACA-H421b) with a final concentration of 0.01 μg/mL. The EC50 of anti-Activin RII neutralizing antibody (Bimagrumab) is approximately 0.01898 μg/mL.

    Protocol
  •  Activin RII APPLICATION

    Inhibition of human GDF-11 protein-induced reporter activity by anti-Activin RII neutralizing antibody.
    This reporter cell was incubated with serial dilutions of antibodies in the presence of human GDF-11 protein with a final concentration of 0.3 μg/mL. The EC50 of anti-Activin RII neutralizing antibody (Bimagrumab) is approximately 0.005157 μg/mL.

    Protocol
  •  Activin RII APPLICATION

    Inhibition of human GDF-8 protein-induced reporter activity by anti-Activin RII neutralizing antibody.
    This reporter cell was incubated with serial dilutions of antibodies in the presence of human GDF-8 protein (Cat. No. GD8-H5344) with a final concentration of 0.01 μg/mL. The EC50 of anti-Activin RII neutralizing antibody (Bimagrumab) is approximately 0.003617 μg/mL.

    Protocol
  • Signaling Bioassay

     Activin RII SIGNALING

    Response to human Activin A protein (RLU).
    The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human Activin A protein (Cat. No. ACA-H421b). The EC50 was approximately 0.00497 μg/mL.

    Protocol
  •  Activin RII SIGNALING

    Response to human Activin A protein (FOLD).
    The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human Activin A protein (Cat. No. ACA-H421b). The max induction fold was approximately 172.

    Protocol
  •  Activin RII SIGNALING

    Response to human GDF-11 protein (RLU).
    The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human GDF-11 protein. The EC50 was approximately 0.2071 μg/mL.

    Protocol
  •  Activin RII SIGNALING

    Response to human GDF-11 protein (FOLD).
    The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human GDF-11 protein. The max induction fold was approximately 192.

    Protocol
  •  Activin RII SIGNALING

    Response to human GDF-8 protein protein (RLU).
    The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human GDF-8 protein (Cat. No. GD8-H5344). The EC50 was approximately 0.04165 μg/mL.

    Protocol
  •  Activin RII SIGNALING

    Response to human GDF-8 protein protein (FOLD).
    The Human Activin RII (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human GDF-8 protein (Cat. No. GD8-H5344). The max induction fold was approximately 331.39.

    Protocol
*如有相关细胞池需求请联系我们

用户评价
发表评论

重要声明

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

前沿进展

 
联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 重要声明